![]() ![]() Finally, Deutsche Bank AG boosted its holdings in shares of 4D Molecular Therapeutics by 2.2% in the 4th quarter. now owns 218,106 shares of the company’s stock worth $3,749,000 after acquiring an additional 1,206 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of 4D Molecular Therapeutics by 0.6% in the 1st quarter. ![]() Bank of New York Mellon Corp now owns 101,322 shares of the company’s stock worth $1,532,000 after acquiring an additional 1,136 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of 4D Molecular Therapeutics by 1.1% in the 1st quarter. MD now owns 18,381 shares of the company’s stock worth $316,000 after acquiring an additional 1,002 shares in the last quarter. MD boosted its holdings in shares of 4D Molecular Therapeutics by 5.8% in the 1st quarter. now owns 48,799 shares of the company’s stock worth $839,000 after acquiring an additional 601 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of 4D Molecular Therapeutics by 1.2% in the 1st quarter. Several institutional investors and hedge funds have recently modified their holdings of the business. Company insiders own 10.70% of the company’s stock. Over the last ninety days, insiders have sold 10,997 shares of company stock worth $216,393. The disclosure for this sale can be found here. Following the sale, the insider now directly owns 1,737 shares in the company, valued at $31,804.47. The shares were sold at an average price of $18.31, for a total value of $41,142.57. Also, insider Scott Bizily sold 2,247 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Thursday, June 1st. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Following the completion of the transaction, the insider now directly owns 4,787,914 shares in the company, valued at $76,606,624. The shares were acquired at an average cost of $16.00 per share, with a total value of $13,600,000.00. In other news, major shareholder Global Investors Lp Viking bought 850,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 9th. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Following the completion of the purchase, the insider now owns 4,787,914 shares of the company’s stock, valued at approximately $76,606,624. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $13,600,000.00. In other 4D Molecular Therapeutics news, major shareholder Global Investors Lp Viking acquired 850,000 shares of the company’s stock in a transaction dated Tuesday, May 9th. Insider Transactions at 4D Molecular Therapeutics ![]() According to data from, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $35.13. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Finally, 92 Resources restated a “reiterates” rating on shares of 4D Molecular Therapeutics in a report on Thursday, May 11th. HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, March 16th. SVB Securities cut their price objective on 4D Molecular Therapeutics from $14.00 to $13.00 and set a “market perform” rating for the company in a report on Thursday, April 13th. Several other analysts have also issued reports on FDMT. 4D Molecular Therapeutics shares last traded at $20.23, with a volume of 341,667 shares traded. The stock had previously closed at $18.27, but opened at $20.85. ![]() ( NASDAQ:FDMT – Get Rating)’s stock price gapped up before the market opened on Thursday after Bank of America raised their price target on the stock from $28.00 to $33.00. ![]()
0 Comments
Leave a Reply. |